Condition: Primary Sjögren's Syndrome · Sponsor: Immunovant Sciences GmbH
This is a Phase 2b, multicenter, randomized, double-blinded, placebo-controlled study to assess the efficacy and safety of IMVT-1402 in adult participants with moderate to severe systemic primary Sjogren's disease (SjD).
This description comes directly from the study's public registry record.
Central Study Contact · 18007970414 · clinicaltrials@immunovant.com
Always discuss trial participation with your own doctor first.
| Site Number - 1027 | Covina, California, United States | Recruiting |
| Site Number - 1007 | El Cajon, California, United States | Recruiting |
| Site Number - 1016 | Menifee, California, United States | Recruiting |
| Site Number - 1029 | Thousand Oaks, California, United States | Recruiting |
| Site Number - 1026 | Upland, California, United States | Recruiting |
| Site Number - 1014 | Fort Collins, Colorado, United States | Recruiting |
| Site Number - 1018 | Hollywood, Florida, United States | Recruiting |
| Site Number - 1021 | Jupiter, Florida, United States | Recruiting |
| Site Number - 1002 | Miami, Florida, United States | Recruiting |
| Site Number - 1004 | Tamarac, Florida, United States | Recruiting |
| Site Number - 1025 | Tampa, Florida, United States | Recruiting |
| Site Number - 1012 | Chicago, Illinois, United States | Recruiting |
+ 109 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06979531